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Conclusion: RT is highly effective for refractory degenerative 
joint diseases. Prognostic factors for outcome can be 
established. Due to minimal side effects and low costs, RT 
represents an excellent treatment compared to conventional 
methods of treatment and surgery in the chronic disease. 
This study confirms by objective criteria the anti-
inflammatory efficacy of low dose RT  
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Purpose or Objective: Hospital General Universitario 
Gregorio Marañon has a long-standing tradition of IOeRT 
(Intraoperative electron Radiation Therapy), with over 1600 
procedures in its 20 year history. Since december 2013, a 
minituarized linear accelerator (LIAC) started to operate in 
our center. We describe the 22 months technical and clinical 
experience with LIAC in our consolidated IOeRT program.  
 
Material and Methods: A review of technical and surgical 
parameters of IOeRT procedures using LIAC was performed 
from December 2013 to October 2015,  
 
Results: From december 2013 to october 2015, 222 
procedures in 185 patients were performed (200 procedures 
with LIAC, 22 transported to a fixed lineal accelerator). 
Cancer types treated were 64 oligorecurrences / 
oligometastases, 34 breast cancers, 44 rectal cancers, 42 
sarcomas, 6 pancreatic adenocarcinomas, 4 esophageal 
neoplasms and 6 other cancer types. The treated anatomic 
sites included 100 cases in pelvis, 40 in abdomen, 25 in limbs, 
34 in breast and 1 in thorax. Relevant operational data 
included 39 days with more than 2 procedures in the same 
working day (22% of total days). Six different applicator sizes 
were selected (range 4-10) with 4 beveled ends (range 0-45). 
Selected energies ranged from 6 to 12. 
 
Conclusion: LIAC is a versatile technology able to be 
incorporated to expert IORT institutions promoting efficient 
action with operative benefits in terms of availability of 
IOeRT components for cancer patients. 
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Purpose or Objective: There has been a rapid growth in the 
number of immuno- and immunoradiotherapy trials over the 
last few decades. Long term durable responses occur, but 
only in a subset of patients. As yet no accurate method of 
identifying those patients most likely to benefit has been 
identified. The factors behind non-response are unclear but 
may include 1) inherent characteristics of the tumour, 2) 
factors influencing immunogenicity such as tumour burden 
and previous treatments and 3) clinical trial design By 
performing a cross sectional analysis of registered clinical 
trials investigating agents thought to stimulate T-cells we 
aimed to detect trends in these factors. In particular we 
aimed to assess the extent to which trials sought to develop 
and identify novel biomarkers of response to immunotherapy. 
 
Material and Methods: A pubmed literature search was 
conducted to establish a list of known T cell checkpoints, co-
stimulatory receptors, ligands, and the antibodies targeting 
these. These search terms were entered into clinical 
trials.gov on October 11, 2014. Study details were 
downloaded as datasets for review by two independent 
assessors. 
 
Results: We identified a total of 350 trials of 
immunomodulatory antibodies targeting PD-1, CTLA4, PD-L1, 
PD-L2, LAG3, B7-H3, CD137, OX40, CD27 and GITR. A 
longitudinal analysis by trial registration date shows a steady 
increase in the number of trials using immunostimulatory 
antibodies As some cancer types are thought to be more 
immunogenic, we looked at the spread of trials by cancer 
type. Unsurprisingly, melanoma trials represent the largest 
proportion, but there has been a shift towards testing 
immunostimulatory antibodies in cancers that are considered 
less immunogenic with a significant increase in trials in NSLC 
when comparing trials registered between 2000 and 2007 and 
those registered between 2008 and 2014. Only 39% of trials 
measured a dynamic immune endpoint as a specified 
outcome. T and B cell number or function were the most 
common markers analysed. However there was a significant 
increase in the measurement of PD-L1 expression in recent 
years.  
 
Conclusion: This analysis provides comprehensive data on the 
rapid growth of immunotherapy trials and highlights that 
despite the multiplicity and variability of potential dynamic 
biomarkers available, there has been a poor uptake. Whilst 
the future of immunotherapy is not in doubt, biomarkers are 
essential to understand the considerable lack of response and 
help guide further trial efforts. 
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Purpose or Objective: New targeted therapies (nTTs) are 
increasingly used in virtually every type of cancer. On the 
other hand radiation therapy (RT) is frequently applied in the 
curative and palliative setting of cancer treatment, 
confronting clinicians more and more with the problem, 
weather a previously initiated nTT-therapy could be 
continued during RT. The aim of this systematic literature 
analysis was to evaluate the toxicity of concomitant 
application of RT with nTTs in a qualitative descriptive 
manner.  
 
Material and Methods: Clinical studies comprising 
concomitant application of RT with EGFR-, VEGFR-, HDAC-, 
proteasom-, BRAF-, m-Tor- or immune-checkpoint-inhibitors 
were eligible. Using fixed search terms 215 publications were 
identified including more than 6000 patients. Forty-eight 
studies analyzed combinations of nTTs with ZNS-RT including 
1164 patients, 45 with head and neck-RT including 2390 
patients, 59 with thoracic RT including 1647 patients, 33 with 
abdominal RT and 30 with pelvic RT including 492 and 1008 
patients respectively.  
 
Results: In most cases combined application produced no 
additional toxicity or a slight increase of the already known 
toxicity profile. Scarcely, however, combination of RT with 
nTTs resulted in serious side effects. These toxicities 
comprised tracheo-bronchial fistulas or GI-bleeding for 
combinations of thoracic or abdominal/pelvic RT with VEGF-
receptor-inhibitors, recall phenomena in combination of RT 
with tyrosinkinase inhibitors e.g. erlotinib and severe 
mucositis, dermatitis or paraplegia (case report) when 
combining RT with ipilimumab. For the majority of these 
